IL-6 plays a critical role in the synergistic induction of human serum amyloid a (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system

Biochemical and Biophysical Research Communications

Volumn 314, Issue 2, 2004, Pages 363-369

  Hagihara, Keisuke ^a   Nishikawa, Teppei ^a   Isobe, Tomoyasu ^a   Song, Jian ^a   Sugamata, Yasuhiro ^a   Yoshizaki, Kazuyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

AA amyloidosis; Anti IL 6 receptor antibody; IL 6; Real time quantitative PCR; SAA; STAT3

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE 2; MONOCLONAL ANTIBODY; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; SERUM AMYLOID A; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AMINO ACID SEQUENCE; ARTICLE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; VALIDATION PROCESS;

EID: 0345743620     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.12.096     Document Type: Article

References (30)

1. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrae acute-phase reactant. FEBS. 265:1999;501-523.
2. Buxbaum J.N., Tagoe C.E. The genetics of the amyloidoses. Annu. Rev. Med. 51:2000;543-569.
3. Falk R.H., Comenzo R.L., Skinner M. The systemic amyloidoses. N. Eng. J. Med. 337:1997;898-908.
4. Savolainen H.A., Isomaki H.A. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J. Rheumatol. 20:1993;1201-1203.
5. Gertz M.A., Kyle R.A. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine. 70:1991;246-256.
6. Liepnieks J.J., Kluve-Beckerman B., Benson M.D. Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1. Biochim. Biophys. Acta. 1270:1995;81-86.
7. Baba S., Masago S.A., Takahashi T.et al. A novel alleic variant of serum amyloid A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemicAA-amyloidosis. Hum. Mol. Genet. 4:1995;1083-1087.
8. ′ -flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis Arthritis Rheum. 44:2001;1256-1272.
9. Nishimoto N., Yoshizaki K., Maeda K.et al. Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with humanized anti-IL6 receptor antibody MRA in rheumatoid arthritis - a phase I/II clinical study of MRA for rheumatoid arthritis in Japan. J. Rheumatol. 7:2003;1426-1435.
10. Betts J.C., Cheshire J.K., Akira S., Kishimoto T., Woo P. The role of NF-κB and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J. Biol. Chem. 268:1993;25624-25631.
11. Charles P., Elliot M.J., Davis D.et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNFα therapy in rheumatoid arthritis. J. Immunol. 163:1999;1521-1528.
12. Nuki G., Bresnihan B., Bear M.B., McCabe D. Long term safety and maintenance of clinical improvement following treatment with Anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum. 46:2002;2838-2846.
13. Scmittgen T.D., Zakrajsek B.A. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J. Biochem. Biophys. Methods. 46:2000;69-81.
14. Zhong H., Simons J.W. Direct comparison of GAPDH, β-actin, cyclosporin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem. Biophys. Res. Commun. 259:1999;523-526.
15. 2 -microglobulin expression in different human cell lines by proinflammatory cytokines Nephrol. Dial. Transplant. 14:1999;2137-2143.
16. Uhlar C.M., Grehan S., Steel D.M., Steinkasserer A., Whitehead A.S. Use of the acute phase serum amyloid A2 (SAA2) gene promoter in the analysis of pro- and anti-inflammatory mediators: differential kinetics of SAA2 promoter induction by IL-1β and TNFα compared to IL-6. J. Immunol. Methods. 203:1997;123-130.
17. Thorn C.F., Whitehead A.S. Differential glucocorticoid enhancement of the cytokine-driven transcriptional activation of the human acute phase serum amyloid A genes, SAA1 and SAA2. J. Immunol. 169:2002;399-406.
18. Gabay C., Genin B., Mentha G., Iynedjian P.B., Lombard P.R., Guerne P.A. IL-1 receptor antagonist (IL-1ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumor cells. Clin. Exp. Immunol. 100:1995;306-313.
19. Steel D.M., Whitehead A.S. Heterogeneous modulation of acute-phase-reactant mRNA levels by interleukin-1β and interleukin-6 in the human hepatoma cell line PLC/PRF/5. Biochem. J. 277:1991;477-482.
20. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2:2002;725-734.
21. Han Y., Brasier A.R. Mechanism for biphasic Rel A NF-κB1 nuclear translocation in tumor necrosis factor α-stimulated hepatocyte. J. Biol. Chem. 272:1997;9825-9832.
22. Rokita H., Loose L.D., Bartle L.M., Sipe J.D. Synergism of interleukin 1 and interleukin 6 induces serum amyloid A production while depressing fibrinogen: a quantitative analysis. J. Rheumatol. 21:1994;400-405.
23. Greha S., Uhlar C.M., Sim R.B., Herbert J., Whitehead A.S. Expression of a biologically active recombinant mouse IL-1 receptor antagonist and its use in vivo to modulate aspects of the acute phase response. J. Immunol. 159:1997;369-378.
24. Kopf M., Baumann H., Freer G.et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 368:1994;339-342.
25. Fantuzzi G., Zheng H., Faggioni R.et al. Effect of endotoxin in IL-1β-deficient mice. J. Immunol. 157:1996;291-296.
26. Bopst M., Hasa C., Car B., Eugster H.P. The combined inactivation of tumor necrosis factor and interleukin-6 prevents induction of the major acute phaseproteins by endotoxin. Eur. J. Immunol. 28:1998;4130-4137.
27. Feldmann M., Bennan F.B., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:1996;397-440.
28. Alonzi T., Maritano D., Gorgoni B., Rizzuto G., Libert C., Poli V. Essential role of STAT3 in the control of acute-phase response as revealed by inducible gene activation in the liver. Mol. Cell. Biol. 21:2001;1621-1632.
29. Zhang D., Sun M., Samols D., Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J. Biol. Chem. 271:1996;9503-9509.
30. Gilmore J.D., Laurence B.L., Persey M.R., Pepys M.B., Hawkins P.N. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. LANCET. 358:2001;24-29.